Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

ClinicalTrials.gov ID: NCT03936777

Public ClinicalTrials.gov record NCT03936777. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome

Study identification

NCT ID
NCT03936777
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Zogenix, Inc.
Industry
Enrollment
412 participants

Conditions and interventions

Interventions

  • ZX008 (Fenfluramine Hydrochloride) Drug

Drug

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 21, 2019
Primary completion
May 7, 2025
Completion
May 7, 2025
Last update posted
Nov 16, 2025

2019 – 2025

United States locations

U.S. sites
26
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
Ep0215 107 Tucson Arizona 85718
Ep0215 144 Los Angeles California 90095
Ep0215 108 San Diego California 92123
Ep0215 101 San Francisco California 94158
Ep0215 103 Aurora Colorado 80045
Ep0215 115 Gulf Breeze Florida 32561
Ep0215 104 Miami Florida 33155
Ep0215 141 Orlando Florida 32803
Ep0215 121 Winter Park Florida 32789
Ep0215 117 Atlanta Georgia 30328
Ep0215 110 Chicago Illinois 60611-2605
Ep0215 140 Bethesda Maryland 20817
Ep0215 112 Boston Massachusetts 02114
Ep0215 109 Rochester Minnesota 55905
Ep0215 132 Roseville Minnesota 55113
Ep0215 105 Hackensack New Jersey 07601
Ep0215 118 Livingston New Jersey 07039
Ep0215 150 Hawthorne New York 10532
Ep0215 142 New York New York 10016
Ep0215 131 Cleveland Ohio 44106
Ep0215 124 Memphis Tennessee 38103
Ep0215 146 Dallas Texas 75207
Ep0215 126 Fort Worth Texas 76104
Ep0215 106 Salt Lake City Utah 84108
Ep0215 119 Seattle Washington 98105
Ep0215 125 Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03936777, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03936777 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →